GlassScriptPhysician profile
Austine Mengnjo
NPI 1770712945
$3,334.64
in general payments reported to CMS, 2019-2025
23 companies · $635 in 2025
The $635 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $35.70 · 2021: $471 · 2022: $296 · 2023: $872 · 2024: $836 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,339 · Education: $3.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,339.49 |
| Education | $3.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $559.17 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $394.26 | 2023-2025 | Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.36 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $355.99 | 2019-2024 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $318.85 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $154.24 | 2023-2024 | |
| Glaxosmithkline, LLC. | $137.99 | 2023 | Benlysta |
| Scpharmaceuticals INC. | $128.26 | 2025 | |
| Daiichi Sankyo INC. | $111.90 | 2019-2024 | Injectafer |
| Alexion Pharmaceuticals, INC. | $105.18 | 2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $102.17 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $85.04 | 2021 | |
| Fresenius USA Marketing, INC. | $73.75 | 2022-2025 | Velphoro |
| Ardelyx, INC. | $68.12 | 2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $66.67 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $63.30 | 2023-2025 | Tarpeyo |
| Genzyme Corporation | $61.52 | 2023-2024 | |
| Amgen INC. | $46.68 | 2020-2025 | Tavneos |
| Takeda Pharmaceuticals U.S.A., INC. | $39.63 | 2020-2023 | Gattex |
| Horizon Therapeutics Plc | $23.50 | 2022 | |
| Lilly USA, LLC | $22.73 | 2024 | Jardiance |
| Shire North American Group INC | $18.13 | 2019 | |
| Novo Nordisk INC | $16.20 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austine Mengnjo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.